Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Cambridge, Massachusetts 02139


Purpose:

The present phase III study aims to evaluate the safety and immunogenicity of MF59-adjuvanted subunit seasonal influenza vaccine and to evaluate the consistency in the manufacturing process of three consecutive lots of MF59-adjuvanted subunit seasonal influenza vaccine with respect to immunogenicity in subjects aged 65 years and older. The active comparator non-adjuvanted seasonal influenza vaccine is approved for use in this age group in the United States and will be used to provide a comparative assessment for immunogenicity and safety.


Criteria:

Inclusion Criteria: - Subjects aged ≥65 years at day of vaccination who are willing and able to comply to study procedures. Exclusion Criteria: - Any suspected impairment of the immune system.


NCT ID:

NCT01162122


Primary Contact:

Study Chair
Novartis Vaccines
Novartis Vaccines


Backup Contact:

N/A


Location Contact:

Cambridge, Massachusetts 02139
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.